Tumor cell surface receptors mediating IDOV-Safe entry

Tumor cell surface receptors mediating IDOV-Safe entry refer to the molecular entities on the surface of malignant cells that facilitate the attachment and internalization of IDOV-Safe, a third-generation oncolytic vaccinia virus (VACV). IDOV-Safe is an intravenously deliverable therapeutic agent developed by ViroMissile, designed to selectively infect and lyse tumor cells while sparing healthy tissue. The entry process primarily involves the initial attachment of the virus to cell surface glycosaminoglycans (GAGs), such as heparan sulfate and chondroitin sulfate, which are often abundantly expressed in the tumor microenvironment. Following attachment, the virus enters the cell either through direct membrane fusion or via macropinocytosis, a process that is significantly enhanced by the activity of the epidermal growth factor receptor (EGFR) on the host cell. Once internalized, the virus exploits the high metabolic and proliferative state of cancer cells to replicate, leading to direct oncolysis and the stimulation of a systemic anti-tumor immune response.

Other names

Vaccinia virus entry receptorsGlycosaminoglycans (GAGs)Heparan sulfateChondroitin sulfateEpidermal growth factor receptor (EGFR) (in the context of VACV entry)

IDOV-Safe enters tumor cells by first attaching to cell surface glycosaminoglycans (GAGs), primarily heparan sulfate and chondroitin sulfate. This is followed by either direct fusion with the plasma membrane or internalization via macropinocytosis, a process mediated by the epidermal growth factor receptor (EGFR) and Rho GTPases.